STOCK TITAN
  1. Home
  2. News
  3. NDRA

ENDRA Life Sciences Inc. - NDRA STOCK NEWS

Welcome to our dedicated page for ENDRA Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on ENDRA Life Sciences stock.

ENDRA Life Sciences Inc. (symbol: NDRA), is revolutionizing the field of ultrasound with its groundbreaking photo-acoustic solutions. The company’s innovations enable medical researchers to screen and modify disease models with unmatched quality and speed. ENDRA Life Sciences has established a global installed base of top-tier institutions utilizing their Nexus-128 system, the only comprehensive 3D imaging solution designed for imaging anatomy, physiology, and labeled molecular targets.

The Nexus 128 is a sophisticated preclinical photoacoustic computed tomography (CT) scanner tailored for small animal imaging. It facilitates quick, non-invasive quantification of physiological parameters, such as tumor vasculature, without the need for ionizing radiation. The fully 3D imaging technology of the Nexus 128 enhances sensitivity compared to traditional slice-based scanners, and its dynamic (4D) photoacoustic CT scans support advanced applications like quantification of probe uptake. Currently, leading imaging laboratories worldwide leverage the Nexus 128 for various research purposes.

Additionally, ENDRA Life Sciences is developing Thermo Acoustic Enhanced UltraSound (TAEUS) technology, which aims to visualize tissue with MRI-like clarity but at a fraction of the cost and at the point of patient care. The TAEUS technology is designed to integrate with approximately 400,000 cart-based ultrasound systems in use globally. Initially, TAEUS focuses on measuring liver fat to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions affecting over a billion people worldwide, for which there are currently no effective diagnostic tools. Beyond liver applications, TAEUS is also being explored for several other clinical uses, such as visualizing tissue temperature during energy-based surgical procedures.

ENDRA Life Sciences continues to push the boundaries of medical imaging technology, collaborating with various partners to further enhance their solutions. Stay updated with the latest achievements, projects, and news from ENDRA Life Sciences to understand their impact and progression in the medical technology landscape.

News

ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe

Rhea-AI Summary
ENDRA Life Sciences Inc. (NDRA) expands its intellectual property portfolio with the issuance of three new patents in the U.S., China, and Europe, bringing the total to 74 worldwide. These patents protect the TAEUS system, enhancing radiofrequency energy absorption, reducing signal noise, and enabling precise temperature monitoring during surgical procedures and thermal ablation. The innovative technology aims to optimize treatment parameters, minimize damage to healthy tissue, and effectively target cancerous cells for improved therapeutic outcomes with reduced side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
-
News

ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology

Rhea-AI Summary
ENDRA Life Sciences Inc. (NDRA) has announced the issuance of a new patent, U.S. Patent No. 11828727, titled 'Thermoacoustic Probe.' This patent further strengthens the company's Intellectual Property (IP) portfolio, bringing the total number of globally issued patents to 71. The '727 patent focuses on a thermoacoustic probe design with an optical transducer and an integrated wedge, enhancing the technology's ability to minimize unwanted signals and optimize radiofrequency signals to targeted regions of interest. ENDRA's Chairman and CEO, Francois Michelon, expressed satisfaction with the company's IP momentum and highlighted the significance of this patent in addressing high unmet clinical needs, especially as the TAEUS technology advances through regulatory review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
none
-
News

ENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference

Rhea-AI Summary
ENDRA Life Sciences Inc. (NDRA) to participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
conferences
News

ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
ENDRA Life Sciences Inc. (NASDAQ: NDRA) reports Q3 2023 financial results and business update, including positive TAEUS clinical data, showcased TAEUS system at major clinical conferences, achieved an intellectual property milestone, and De Novo request advanced to next stage of review at FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
earnings
-
News

ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents

Rhea-AI Summary
ENDRA Life Sciences Inc. (NASDAQ: NDRA) announces the issuance of three new patents, including one in the U.S. and two in China, bringing their intellectual property portfolio to 70 issued patents worldwide. The patents enhance the IP protection for the novel TAEUS® system, focusing on thermoacoustic probe, transducer with integrated switch, and acoustically isolated thermoacoustic imaging probe. Francois Michelon, ENDRA's Chairman and CEO, emphasizes the significance of these patents in addressing unmet clinical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
none
-
News

ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023

Rhea-AI Summary
ENDRA Life Sciences Inc. (NDRA) to Report Q3 2023 Financial Results on November 14, 2023, After Market Close
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
conferences earnings
News

ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023

Rhea-AI Summary
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will host an offsite panel discussion at the American Association for the Study of Liver Diseases (AASLD) annual meeting. The panel will focus on managing Metabolic-Associated Steatotic Liver Disease (MASLD) and feature three key opinion leaders in hepatology, endocrinology, and radiology. ENDRA will also showcase its TAEUS technology at the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
conferences
-
News

Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023

Rhea-AI Summary
ENDRA Life Sciences announces acceptance of clinical abstract on Thermoacoustic assessment of fatty liver disease for presentation at Steatotic Liver Disease Summit 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
none
-
News

ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA

Rhea-AI Summary
ENDRA Life Sciences' De Novo request for the TAEUS liver system has advanced to substantive review with the FDA, potentially strengthening its competitive position in the non-invasive assessment of fatty liver tissue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.31%
Tags
none
News

ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents

Rhea-AI Summary
ENDRA Life Sciences announces the issuance of three new patents, bringing their global intellectual property portfolio to 67 issued patents. The patents strengthen the TAEUS system's proprietary position and provide protection for its novel hybrid ultrasound and thermoacoustic imaging technology. The patents cover a radio frequency applicator, a method and system for monitoring tissue temperature, and a method and system for determining fractional fat content of tissue. These patents advance and protect ENDRA's thermoacoustic imaging systems in areas with high unmet clinical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of ENDRA Life Sciences (NDRA)?

The current stock price of ENDRA Life Sciences (NDRA) is $5.09 as of November 22, 2024.

What is the market cap of ENDRA Life Sciences (NDRA)?

The market cap of ENDRA Life Sciences (NDRA) is approximately 2.7M.

What does ENDRA Life Sciences Inc. specialize in?

ENDRA Life Sciences specializes in advanced ultrasound technologies, including the Nexus-128 system and Thermo Acoustic Enhanced UltraSound (TAEUS).

What is the Nexus-128 system?

The Nexus-128 system is a preclinical photoacoustic computed tomography (CT) scanner for small animal imaging, providing 3D imaging of anatomy, physiology, and labeled molecular targets.

What are the applications of the TAEUS technology?

TAEUS technology is used for visualizing tissue like MRI at a fraction of the cost, initially focusing on assessing liver fat for conditions like NAFLD and NASH.

Who uses the Nexus-128 system?

Leading imaging laboratories and top-tier institutions around the world utilize the Nexus-128 system for various research purposes.

How does the Nexus-128 system benefit medical research?

The Nexus-128 system offers quick, non-invasive quantification of physiological parameters without ionizing radiation, enhancing research accuracy and efficiency.

What are NAFLD and NASH?

NAFLD (Non-Alcoholic Fatty Liver Disease) and NASH (Non-Alcoholic Steatohepatitis) are chronic liver conditions that affect over a billion people globally.

How is TAEUS technology integrated into existing ultrasound systems?

TAEUS technology is designed to work alongside approximately 400,000 cart-based ultrasound systems currently in use around the world.

What makes ENDRA's imaging technology unique?

ENDRA's imaging technology, including the Nexus-128 and TAEUS, offers high sensitivity, non-invasive procedures, and cost-effective solutions compared to traditional imaging methods.

Are there other clinical applications for TAEUS technology?

Yes, beyond liver fat measurement, TAEUS technology is being explored for other clinical uses such as visualizing tissue temperature during energy-based surgical procedures.

Where can I find the latest news and updates about ENDRA Life Sciences?

You can stay updated with the latest news and developments of ENDRA Life Sciences on their official website and stock market websites like StockTitan.

Stock NDRA logo
ENDRA Life Sciences Inc.

Nasdaq:NDRA

NDRA Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

NDRA Stock Data

2.68M
516.81k
0.28%
0.49%
4.64%
Diagnostics & Research
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
ANN ARBOR